TD Cowen raised the firm’s price target on Endava (DAVA) to $36 from $35 and keeps a Buy rating on the shares. The firm said progress was evident in 1Q and the 2025 guide was importantly affirmed. Top clients better, choppiness lingers, but stability is forming which is key to sustained recovery. Implied 2H revenue acceleration is apt to be the main debate, though stable demand backdrop prudently assumed.